Challenges in allogeneic mesenchymal stem cell-mediated cardiac repair.


Autologous mesenchymal stem cells (MSCs) have been proven safe in phase I and II clinical trials in patients who have suffered a myocardial infarction. However, their potential for proliferation and differentiation decreases with age, which limits their efficacy in elderly patients. Allogeneic MSCs offer several key advantages over autologous MSCs… (More)
DOI: 10.1016/j.tcm.2011.12.002


  • Presentations referencing similar topics